Explore every episode of the podcast Fat Science

What do new drug reports really mean for your treatment?

Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues.

KEY TAKEAWAYS

• Understanding the difference between efficacy estimand and treatment policy estimand.

• Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes.

• Semaglutide's effectiveness in children and its implications.

NOTABLE QUOTE

"Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper

LINKS & RESOURCES

Learn more about Diabesity Foundations: learn.diabesityinstitute.org

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Diabesity Institute: diabesityinstitute.org

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you ever felt that diets don't work for you?

Mark Wright, Andrea Taylor, and Dr. Emily Cooper dive deep into the science of metabolism, challenging the myths surrounding diets and weight gain. With personal stories and expert insights, they explore how metabolic function and genetics play vital roles in our health.

KEY TAKEAWAYS

• Diets often don't address underlying metabolic issues.

• Metabolic syndrome involves multiple health systems and requires comprehensive care.

• GLP-1 medications have changed the treatment landscape for metabolic dysfunction.

NOTABLE QUOTE

"It's not your fault... you were dealt not the best hand genetically." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Can metabolic dysfunction be the cause of anxiety?

Join Dr. Emily Cooper, Andrea Taylor, and guest Alessio De Martis as they explore the fascinating intersection of metabolic health, anxiety, and the struggle with traditional diet advice. Learn how under-fueling can exacerbate metabolic issues and what that means for your overall health.

KEY TAKEAWAYS

• Alessio's experience highlights the struggle of self-managing metabolic health in Europe.
• Under-fueling can worsen metabolic dysfunction, disrupting body stability.
• The body's response to hypoglycemia can mirror symptoms of anxiety.

NOTABLE QUOTE

"If you have a history of hypoglycemia, you're gonna have a lot less tolerance than other people." — Dr. Emily Cooper

GUEST BIO

Alessio De Martis is a 41-year-old listener from Rome, Italy, who shares his experiences with metabolic dysfunction, hypoglycemia, and anxiety. His journey represents the challenges faced by many in understanding their metabolic health.

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What's the back-to-school metabolism shift all about?

The return to a school routine can have surprising impacts on metabolic health. Dr. Emily Cooper explains how sleep, nutrition, and scheduling affect metabolism, and offers practical advice for parents managing these transitions.

KEY TAKEAWAYS

• Sleep quality is crucial for kids' and parents' metabolic health.

• Proper fueling before, during, and after exercise is essential for kids.

• Maintaining a consistent schedule can help manage stress and metabolism.

NOTABLE QUOTE

"Fueling the workout enhances our fitness basically, and reduces our stress hormones and strengthens our metabolism." — Dr. Emily Cooper

LINKS & RESOURCES

Studies on sleep and insulin resistance

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Diabesity Institute: diabesityinstitute.org

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Is menopause impacting your weight and health in unexpected ways?

In this episode, the hosts tackle an assortment of listener questions about weight loss, metabolic health, and menopause. They delve into the intricacies of medication tolerance, the ethics of unregulated weight loss drugs, and the physiological changes that can affect women during menopause.

KEY TAKEAWAYS

• Understanding metabolic and hormonal impacts during menopause is crucial.
• Unregulated weight loss drugs pose significant risks and ethical concerns.
• Medication tolerance and side effects can vary greatly among individuals.

NOTABLE QUOTE

"It's not your fault." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What are the top causes of metabolic disruption?

In this informative episode, Dr. Emily Cooper dives into the factors that quietly sabotage metabolic health. From the intricacies of sleep to the surprising connection between love and metabolism, listeners will learn what enhances or damages their metabolic system.

KEY TAKEAWAYS

• Sleep is crucial for metabolic and hormonal balance.

• Weight cycling severely impacts metabolic health.

• Underlying stress and emotional wellbeing affect metabolism.

NOTABLE QUOTE

"Everyone has strengths and limitations, let's put it that way." — Dr. Emily Cooper

LINKS & RESOURCES

Mechanical Eating Handout: Available on our Patreon page.

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Do you ever wonder how medications like Wegovy and Mounjaro influence your metabolic health?

Dr. Emily Cooper, along with Andrea Taylor and Mark Wright, dives into listener questions about maintaining metabolic health when medication coverage is lost, understanding the role of leptin after weight loss, and the effects of medications like Mounjaro. They also explore the injection site reactions and the complex interplay between thyroid, exercise, and inflammation.

KEY TAKEAWAYS

• Loss of medication insurance coverage can significantly impact treatment, but alternative options like pills may be available.

• Leptin levels differ by gender; they're naturally lower in men due to different body composition.

• Fasting can disrupt hunger signals and glucose regulation, particularly following intermittent fasting.

• Injection site reactions are common but switching medications or techniques might alleviate symptoms.

NOTABLE QUOTE

"Obesity is a physical sign of underlying metabolic dysfunction." — Dr. Emily Cooper

LINKS & RESOURCES

To register for course: https://learn.diabesityinstitute.org/products/live_events/live-virtual-update-event

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Is wildfire smoke affecting more than just your lungs?

Poor air quality affects not only respiratory health but also metabolic functions. Wildfire smoke can trigger inflammation, oxidative stress, and hormone release, leading to metabolic disturbances.

KEY TAKEAWAYS

• Wildfire smoke can impact metabolism, leading to insulin resistance.

• Stress hormones released during smoke exposure can raise blood sugar levels.

• Air pollution is linked to increased risk of metabolic syndrome components.

NOTABLE QUOTE

"When there were wildfire events, within days, the admissions for diabetes increased." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Is it really a good idea to get medical care from online pharmacies posing as clinics?

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dig into a Yale secret shopper study that tested 49 websites selling GLP-1 medications online. The websites look and market like medical clinics, but the study found that most patients never spoke to a clinician at all before getting a prescription. Dr. Cooper, Mark, and Andrea unpack what real medical care requires, why these platforms skip it, and what that means for anyone considering this route.

KEY TAKEAWAY

• Two-thirds of the sites in the study issued a prescription with no clinician contact of any kind — despite marketing themselves as medical clinics.

• Fewer than 40% asked for any clinical measurement (blood pressure, labs, etc.), and only 18% asked whether the patient even had a primary care doctor.

• Many of these sites are financially connected to compounding pharmacies and use leading questions to push add-ons that create untested drug combinations.

• Real medical care means a full history, objective labs, and ongoing monitoring — not a five-minute questionnaire and an automatic credit card charge.

NOTABLE QUOTE

"The marketing appears to be a medical clinic or a medical company, when in fact it's really just a sale of a drug." Dr. Emily Cooper

LINKS & RESOURCES

Study published in JAMA on the secret shopper findings

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Does exercise really boost metabolism, or is there a hidden truth?

In this episode, Dr. Emily Cooper uncovers the science behind why exercise isn’t just about burning calories. Dive into the fascinating world of myokines, the chemical messengers released by muscles that impact everything from mood to inflammation. Discover why it's not your fault if exercise alone isn't solving your metabolic issues.

KEY TAKEAWAYS

• Exercise impacts more than calorie burn; it's a signaling system for the body.

• Myokines, released during exercise, affect organs like the brain and liver.

• Muscle contractions broadcast vital signals affecting overall health.

NOTABLE QUOTE

"Exercise is more than burning energy; it's communication throughout the body." — Dr. Emily Cooper

LINKS & RESOURCES

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

To register for course: https://learn.diabesityinstitute.org/products/live_events/live-virtual-update-event

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

How does biology affect our perception of body size?

Dr. Emily Cooper answers listener questions about body dysmorphia and metabolic dysfunction. Mark and Andrea discuss the challenges with compounded medications and the implications of insurance-driven diet requirements.

KEY TAKEAWAYS

• Body dysmorphia can have biological components related to metabolic dysfunction.

• Compounded medications may lack the testing and safety guarantees of brand names.

• Insurance requirements often lack a medical basis and can hinder proper treatment.

NOTABLE QUOTE

"The altered body image perception may be linked to metabolic signals." — Dr. Emily Cooper

LINKS & RESOURCES

None mentioned.

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Why is your fat talking to you?

In the latest solo episode, Dr. Emily Cooper, Andrea Taylor, and Mark Wright explore groundbreaking research into metabolic health. Learn why the scale doesn't always reflect metabolic risk, and discover the science behind fat's active role in the body.

 KEY TAKEAWAYS

• Metabolic dysfunction cannot be judged by scale weight alone.

• Visceral fat is a stronger predictor of heart failure than BMI.

• Hormonal environments profoundly affect fat storage and health risks.

NOTABLE QUOTE

"Your fat is talking to you." — Andrea Taylor

LINKS & RESOURCES

Obesity Reviews Paper

Immunological Reviews Journal Article

European Congress on Obesity Study

 Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Is your brain starving for glucose?

In this episode, Dr. Emily Cooper explores the critical role of the brain as a metabolic organ and its dependence on glucose and insulin. Listeners will learn why good sleep and a holistic lifestyle are vital for cognitive health.

KEY TAKEAWAYS

• The brain uses about 20% of your body's energy at rest.

• Insulin plays a non-fuel role in brain function, supporting neural connections and mood.

• Sleep is essential for the brain's waste clearance system, the glymphatic system.

• Insulin resistance in the brain is linked to cognitive decline and dementia.

• Exercise, a balanced diet, and social engagement are key to brain health.

NOTABLE QUOTE

"The brain is the most metabolically active organ in our body." — Dr. Emily Cooper

LINKS & RESOURCES

JAMA: US POINTER Study on Cognitive Decline

Novo Nordisk: EVOKE & EVOKE Plus Trials

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Is it normal for GLP-1 medications to become less effective over time?

Dr. Emily Cooper discusses listener questions about the nuances of metabolic health and the real reasons behind weight fluctuations and food cravings. With insights into GLP-1 medications, mechanical eating, and more, the episode aims to debunk myths and provide science-based encouragement.

KEY TAKEAWAYS

• Trusting your body's hunger signals can prevent metabolic slowdown.

• Mechanical eating can help manage sugar cravings and maintain metabolic health.

• Navigating pediatric metabolic issues requires understanding genetic influences and appropriate medical intervention.

NOTABLE QUOTE

"It's not your fault. Trust your body and step up to the higher end of your metabolic flexibility." — Dr. Emily Cooper

LINKS & RESOURCES

American Board of Obesity Medicine: obesitymedicine.org

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you ever wondered why your body holds onto weight despite your best efforts?

In this eye-opening episode, Dr. Cooper reveals groundbreaking research showing that 100% of healthy adults carry at least six different plastic-related chemicals in their bodies daily. These endocrine disruptors don't just affect your hormones - they may be stored in your fat tissue and could be a hidden driver of metabolic dysfunction. The good news? New Australian research proves you can dramatically reduce these chemicals in just one week with targeted changes.

KEY TAKEAWAYS

• Every single person tested had at least 6 plastic chemicals in their urine, with food packaging being the primary source

• Participants cut phthalate levels by 38-54% and BPA by 60% in just 7 days with adjustments in reducing plastic exposure in food and food packaging

• Ultra-processed foods introduce plastic chemicals through multiple processing and packaging steps

• Certain chemicals like DEHP may be stored in fat tissue and released during weight loss

• Heat accelerates plastic migration into food - avoid microwaving in plastic and pouring hot food into plastic containers

• Simple swaps like choosing fresh over canned foods and using glass containers make significant impacts

• The EPA research office studying these chemicals was recently eliminated, removing key consumer protections

NOTABLE QUOTE

"People who switched to the low plastic food and kitchenware cut the phthalates excretion by 38 to 54% in one week and they cut their BPA excretion by 60% in one week." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What happens when GLP-1 medications stop working the way you hoped they would? In this mailbag episode, Dr. Emily Cooper answers listener questions about fasting, insulin levels, PCOS, lipedema, plateaus on Zepbound, and the complicated reality behind metabolic dysfunction. From the dangers of under-fueling to why individualized treatment matters so much, this conversation unpacks the science behind weight resistance with clarity and compassion.Key Takeaways

• Why fasting and restrictive eating may worsen metabolic adaptation

• The real role insulin plays in metabolic health

• How PCOS and lipedema complicate weight loss treatment

• Why some people plateau on GLP-1 medications over time

• The importance of fueling, muscle preservation, and individualized care

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Could you have metabolic dysfunction even at a normal weight?

This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone.

KEY TAKEAWAYS

• Weight and metabolic health are not the same thing - you can be metabolically unhealthy at any size

• Normal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providers

• Key screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRP

• Metabolic dysfunction can start in your 20s and take decades to develop into serious disease

• Both normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weight

• Early screening and treatment can prevent catastrophic health outcomes later in life

• The liver plays a crucial role in metabolism and can become insulin resistant regardless of body weight

NOTABLE QUOTE

"You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Appendix: Key References

Primary literature supporting this episode

•       Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023.

•       Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025.

•       Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024.

•       Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity.

•       International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes.

Mechanism references

•       MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023.

•       Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship.

•       Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026.

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told your metabolism is broken and there's nothing you can do about it?

This mailbag episode tackles tough questions about medication effectiveness, unexpected side effects, and the complex realities of treating metabolic dysfunction. Dr. Cooper addresses why some people regain weight while still on GLP-1s, explores the connection between hair loss and weight loss medications, and explains why leptin levels can remain stubbornly low even with proper nutrition.

KEY TAKEAWAYS

• Weight regain while on GLP-1 medications is more common than most people realize

• Hair loss from weight loss medications is usually related to nutrient deficiencies, not the medication itself

• Leptin dysfunction involves both hormone levels and signaling pathways throughout the body

• Hypoglycemia after meals often indicates complex metabolic issues that require specialized testing

• Starting elderly patients on GLP-1s requires careful monitoring of nutrition, blood pressure, and side effects

• Mechanical eating differs from intuitive eating and remains important even when medications are working

• Annual weight loss rates of 10% or higher indicate medications are still effective

NOTABLE QUOTE

"It is not uncommon to see the weight go up while on these meds, contrary to what people think. They're great, but we always wanna point out some people don't even respond to these." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Ever wonder why you can improve your health but still feel like you're failing because the scale isn't cooperating?

Dr. Cooper breaks down groundbreaking new clinical guidelines from three major obesity organizations that are completely reframing what success in obesity treatment actually means. For the first time, these groups are saying quality of life, energy levels, and overall health matter more than the number on the scale.

KEY TAKEAWAYS

• Three major obesity organizations worked collaboratively to issue guidelines prioritizing quality of life over weight loss as primary treatment goals

• Guidelines explicitly address medical stigma as a structural barrier to care requiring systemic change

• Treatment is positioned as long-term management similar to other chronic conditions like thyroid disorders

• Document notably avoids calorie restriction language, focusing instead on healthy lifestyle alongside medication

• Setmelanotide receives strong recommendation for rare genetic obesity conditions with available genetic testing

• Strong medication recommendations now include GLP-1s like semaglutide and tirzepatide, plus bupropion-naltrexone combination

NOTABLE QUOTE

"Nobody ever asked. Nobody ever looked. Nobody ever said anything. I was like, 'I think there's something wrong with my metabolism or something because I'm not eating a ton.' They're like, 'Well, you must be.' And I'm like, 'N- n- no, I don't think so. I mean, unless it's happening when I'm sleeping. I don't know.'" — Andrea Taylor

Reference Link

Alexander L, Purnell JQ, et al. Pharmacological management of obesity in adults: a clinical guidance statement from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition. Obesity. 2026;34(4):851–870. doi:10.1002/oby.70164 https://onlinelibrary.wiley.com/doi/10.1002/oby.70164 

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told you have PCOS but nothing seems to help?

In May 2024, after 14 years of global collaboration involving 56 organizations and 22,000 stakeholders, the medical community officially changed PCOS to PMOS - and the reason why reveals everything that's been wrong with how this condition has been understood and treated for decades. Dr. Cooper breaks down why this isn't just a name change, but a complete reframe that puts metabolic dysfunction at the center where it belongs.

KEY TAKEAWAYS

• PCOS is now officially called PMOS - Polyendocrine Metabolic Ovarian Syndrome - shifting focus from ovarian problems to metabolic dysfunction
• 70 million women globally are affected during reproductive years, with 70% remaining undiagnosed
• The condition can occur at any weight and is driven by insulin resistance and other metabolic signals, not ovarian problems
• Treatment should focus on metabolic health rather than weight loss or ovarian interventions
• The name change parallels similar shifts in medicine like MASLD replacing non-alcoholic fatty liver disease

NOTABLE QUOTE

"Most patients with this label that they've had in the past, the PCOS label, feel a sense of hopelessness, and even join support groups and things like that, and thinking that this will be a condition they have forever. And what I try to do is explain, no, this is just a physical manifestation of the metabolic disruption that we treat all the time" — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told it's just calories in calories out while your lived experience says otherwise?

In this mailbag episode, Dr. Cooper addresses complex metabolic questions from listeners worldwide. From eating disorders requiring specialized care to GLP-1 plateau management, each question reveals how individual biology trumps one-size-fits-all solutions.

KEY TAKEAWAYS

• Eating disorders like anorexia require comprehensive medical team treatment, not self-management approaches

• Side effects from GLP-1 medications often improve with consistent eating patterns and adequate nutrition

• The calories in calories out model ignores the biological complexity of how your body actually burns fuel

• PCOS responds well to metabolic treatments because it's driven by underlying insulin and hunger hormone imbalances

• Sleep deprivation and chronic stress significantly impact GLP-1 effectiveness and overall metabolic function

• Bioidentical progesterone may help perimenopause sleep issues without the metabolic side effects of older formulations

• Stroke survivors may experience hypothalamic obesity that responds remarkably well to GLP-1 medications

NOTABLE QUOTE

"If that really worked, imagine, you know, would we actually need these sophisticated medications that are so groundbreaking? Would we have had decades and decades, or actually centuries of failed, you know, diet experiences by so many people?" — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are your legs painful to touch and resistant to weight loss despite your best efforts?

Dr. Ellen Derrick, a vascular surgeon and lipedema specialist, reveals the truth about this misunderstood condition affecting 20% of women worldwide. Lipedema isn't obesity - it's a fat cell disorder where tissue responds abnormally to inflammation, creating painful, swollen areas that don't respond to traditional weight loss methods. She explains the connection between lipedema and venous insufficiency, why patients are often dismissed by doctors, and the emerging treatments offering hope.

KEY TAKEAWAYS

• Lipedema affects 20% of the female population but is routinely misdiagnosed as obesity
• The condition involves abnormal fat cell response to inflammation, creating painful tissue that resists weight loss
• 86% of lipedema patients also have venous insufficiency, creating a perfect storm of symptoms
• Ankle cuffs, knee pouches, and saddlebags are classic physical signs that patients often notice from puberty
• GLP-1 medications like tirzepatide may help reduce inflammation and tissue tenderness
• Lipedema reduction surgery exists but lacks insurance billing codes, making access challenging
• A formal medical recognition campaign is underway to establish diagnostic codes by 2026-2027

NOTABLE QUOTE

"The medical community really has done an outstanding job, in a way, gaslighting these patients. These patients have been aware that something is different about their body and their legs since puberty." — Dr. Ellen Derrick

GUEST BIO

Dr. Ellen Derrick is a Seattle-based board-certified vascular and general surgeon with over 20 years of clinical experience and a Master of Public Health from the University of Washington. She founded Boxbar Vascular, specializing in lipedema and related metabolic conditions, and serves on the board of the Lipedema Society working toward formal medical recognition of the condition.

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down three breaking metabolic health stories in this quick bonus episode — from a newly approved oral GLP-1 to a major price drop for Medicare patients.

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you ever wondered if you should get liposuction when you need skin removal surgery after major weight loss?

In this mailbag episode, Dr. Cooper, Mark, and Andrea tackle questions from listeners around the world, from Germany to Alabama to Chicago. They discuss why restricting calories while on GLP-1 medications can actually work against you, address the reality of finding metabolic-informed doctors internationally, and explain the science behind fat cell removal during skin surgeries. Plus, they share details about the newly approved oral GLP-1 medication orforglipron (Foundayo) and why vegetables, fats and starches matter even when you're protein-focused.

KEY TAKEAWAYS

• Restricting calories on GLP-1 medications can lower your metabolic rate and weaken your body's natural GLP-1 production

• Liposuction during skin removal surgery may disrupt leptin signaling, though males may be less affected than females due to naturally lower leptin levels

• Finding metabolic-informed doctors globally remains challenging, but obesity medicine certification and Canadian and European obesity organizations may offer better resources

• The oral GLP-1 medication orforglipron will likely be less expensive but also less effective than dual-agonist medications like tirzepatide

• Mechanical eating without calorie counting often produces better long-term results than restrictive approaches

• Vegetables provide essential micronutrients and support healthy microbiome function that protein alone cannot replace

• Major weight loss surgery like tummy tucks is serious surgery that requires careful consideration and qualified surgeons

NOTE: This episode was recorded before Foundayo (orforglipron) was released on the market. The price is the same as the Wegovy pill. Listen to our episode - “New Obesity Drugs” for more information https://podcasts.apple.com/us/podcast/fat-science/id1715377331?i=1000762362056

NOTABLE QUOTE

"If only they didn't fall into that diet cycle, some of them, their weight would be a hundred pounds less. Yes, it might be still elevated, but a large chunk of that weight was caused by the diet cycle itself." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Ever hear someone say GLP-1 medications cause osteoporosis or make your hair fall out?

This episode tackles the top 10 biggest myths about GLP-1 medications flooding social media and separates the science from the scary headlines. Dr. Cooper breaks down what's actually happening in your body versus what the internet claims, from bone density concerns to the dreaded "Ozempic face."

KEY TAKEAWAYS

·  GLP-1 medications don't cause osteoporosis - inadequate nutrition while losing weight can weaken bones

·  Hair loss is typically from nutritional deficits, not the medication itself

·  These drugs slow gastric emptying but don't cause permanent stomach paralysis

·  Weight regain after stopping is expected since you're treating a chronic medical condition

·  Muscle loss comes from eating too little, not from the medication directly

·  The thyroid cancer warning comes from rodent studies and hasn't been observed in humans

·  GLP-1s actually protect the pancreas rather than damage it

NOTABLE QUOTE

"Metabolic dysfunction is biological, it's not something within your means to correct just through lifestyle strategies." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The obesity medication landscape just changed — again. One brand-new pill is already in pharmacies, and five more are in various stages of approval. But the real story isn't the drugs themselves: it's what they're revealing about how your metabolism actually works, and why willpower was never the problem.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down six metabolic medications — two newly FDA-approved and four in the pipeline — covering everything from a flexible new oral GLP-1 pill to drugs that target the brain's central metabolic pathway directly. Dr. Cooper explains the science behind each one, who might benefit, and what the pipeline tells us about the future of metabolic care. This is the most comprehensive drug update the show has done, and it arrives at a moment when the field is moving faster than ever.

Key Takeaways

• Foundayo (orforglipron), approved April 1st, is the first small molecule oral GLP-1 — no empty stomach requirement, no cold chain, and potentially lower production costs long-term.

• The amylin hormone may uniquely address both "I'm nourished" and "I weigh enough" signals in the brain — making the amylin pathway a powerful and underutilized target.

• Retatrutide (Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors) is showing unprecedented effectiveness plus significant non-scale benefits, including fatty liver reduction — but is still years from approval.

• The brain's melanocortin 4 receptor is the CEO of metabolism — regulating energy expenditure, appetite, and insulin — and new drugs targeting it represent the deepest intervention yet.

• Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost.

Notable Quote

"Everybody focuses on appetite, and you just need to eat less. But now with these medications and how they actually affect our biology, it becomes very clear that there's so much more to this." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told insulin resistance testing doesn't exist or wondered if you're increasing your GLP-1 dose too quickly?

Dr. Cooper, Andrea, and Mark tackle listener questions from around the world, addressing common concerns about insulin resistance testing availability, managing severe GI side effects from higher doses, interpreting DEXA scan results, and developing sustainable maintenance strategies. They discuss the difference between hunger and food noise, explain why winter illness might stall weight loss, and share insights about visceral fat concerns even at normal weight.

KEY TAKEAWAYS

• Insulin resistance can be tested through fasting insulin and glucose ratios, even in countries where insulin testing is less common

• Rapid weight loss rates above 15% annually may indicate no need for dose increases

• Severe GI side effects warrant investigation beyond medication adjustment, including gallbladder evaluation

• DEXA scans provide valuable visceral fat measurements, but results should be interpreted alongside overall health markers

• Maintenance strategies should focus on nutritional stability before considering medication tapering

NOTABLE QUOTE

"It's not that the medicine causes the rebound weight gain, it's that with the medication in there, the body is getting better signals, and then you go and take the medication away and you're in the same boat." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are you getting a GLP-1 prescription from someone who's never examined you?

Dr. Vin Gupta, pulmonologist and former Chief Medical Officer at Amazon, joins Dr. Cooper to expose the dangerous gap between legitimate obesity medicine and the unregulated direct-to-consumer market. This conversation reveals why proper medical evaluation matters and how profit-driven platforms are exploiting desperate patients.

KEY TAKEAWAYS

• GLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribing
• Direct-to-consumer microdosing platforms lack FDA approval and proper medical oversight
• The erosion of trust in healthcare has created opportunities for unregulated treatments
• Comprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plans
• Technology should enhance medical care, not replace proper physician evaluation

NOTABLE QUOTE

"I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." — Dr. Emily Cooper

GUEST BIO

Dr. Vin Gupta is a pulmonologist, public health expert, and medical analyst for NBC News. He served as Chief Medical Officer at Amazon and has dedicated his career to translating complex science into actionable health insights at both individual and population levels.

GLOSSARY

GLP-1 medications: Glucagon-like peptide-1 receptor agonists, medications that help regulate blood sugar and appetite, including brand names like Ozempic, Wegovy, and Zepbound

Microdosing: Taking smaller amounts of medication than officially prescribed or approved

Direct-to-consumer (D2C): Healthcare services that bypass traditional medical settings, often delivered through apps or online platforms

HRV: Heart rate variability, a measurement of the variation in time between heartbeats

Pre-diabetes: Blood sugar levels that are higher than normal but not high enough to be diagnosed as type 2 diabetes

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What really happens when you stop GLP-1 medications — and are the headlines telling you the whole story? The answer is more nuanced than social media wants you to believe.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down four recent studies on GLP-1 treatment outcomes, weight regain, and a groundbreaking new drug that could preserve lean mass during treatment. They walk through the methodology behind each paper, explain why two studies asking the same question got opposite answers, and reveal what a new monoclonal antibody called bimagrumab could mean for the future of metabolic treatment.

Key Takeaways

• When you stop treating any chronic metabolic condition, the condition returns — that's not failure, that's biology.

• Real-world data showed 56% of people who stopped filling GLP-1 prescriptions maintained or continued losing weight — likely because they continued working with their clinician on alternative treatments.

• A new monoclonal antibody called bimagrumab showed 11% body weight reduction on its own, while simultaneously increasing lean mass by 3% — without affecting appetite.

• When combined with semaglutide, bimagrumab reduced lean mass loss from 28% to just 11% of total weight lost.

• Not eating enough while on GLP-1s drives greater lean mass loss — nutrition is still the best tool for preserving muscle.

Notable Quote

"It wasn't my failure and it was disease underneath everything. Finding that out — that it wasn't my fault — that was the miracle of the whole process to me." — Andrea Taylor

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations

Ever wonder why fasting worked at first — then stopped? Or why you lost 80 pounds only to gain back 100?

In this mailbag episode, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the most misunderstood topics in metabolic health. From the harsh reality of fasting culture to the surprising metabolic challenges faced by normal-weight individuals, this conversation validates what you've been experiencing and explains the science behind it. You'll also hear why GLP-1 medications aren't just weight loss drugs, why your body might be fighting you even when you're doing everything right, and what happens when your job — like shift work or firefighting — disrupts your metabolism for years.

KEY TAKEAWAYS

• You can have metabolic dysfunction at a normal weight with what appear to be normal labs, for example, when insulin is over suppressed from chronic under-fueling or overexercising
• Fasting triggers the same biological adaptation as any restrictive diet and typically results in weight regain that's 22 percent higher than starting weight
• Food noise is biological, not psychological, and stems from an imbalance of hormones and neurotransmitters signaling nutritional insecurity
• GLP-1 medications may improve immune function because metabolic health and immunity are deeply connected
• Shift work and chronic sleep disruption can cause real metabolic damage by weakening leptin signals, increasing insulin resistance, and amplifying hunger hormones

NOTABLE QUOTE

"You can't trick your body. You have to have that foundational fueling in there." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are you getting eight hours in bed but still waking up exhausted?

Dr. Emily Cooper shares groundbreaking findings from nearly 15,000 patient encounters at her metabolic clinic. The data reveals surprising connections between stress, eating frequency, sleep quality, and metabolic health — and why the number of hours you spend in bed doesn't tell the whole story.

KEY TAKEAWAYS

• Over 60% of patients reported trouble staying asleep, even when they got eight hours in bed
• Higher stress levels were associated with double the rate of low energy and significantly worse sleep quality
• Eating frequency matters — patients eating five times per day reported the best sleep and highest energy levels
• The sweet spot between meals is two to four hours — longer gaps were linked to sleep disruption and low energy
• Any amount of alcohol was associated with fragmented sleep, regardless of stress levels
• Nearly 65% of patients were not hydrating adequately throughout the day

NOTABLE QUOTE

"If your cortisol goes high, we can get the same effects that happen when we take steroids, which we know promote pre-diabetes, insulin resistance, weight gain." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Think squashing your post-meal glucose spike is the healthy thing to do? What if that flat line on your CGM is actually telling your brain you didn't eat — and slowing your metabolism as a result?

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor open the mailbag to tackle listener questions from around the world — Australia, New Zealand, and across the U.S. They dig into hormone replacement therapy and metabolism, why your GLP-1 medication might be causing hair loss, what a normal blood sugar response actually looks like, and how lipedema differs from obesity. Dr. Cooper also revisits metabolic syndrome and why it's not outdated — just underutilized.

Key Takeaways

• Hormone replacement therapy isn't a reliable tool for improving metabolism — it's better suited for symptom relief and bone health in specific situations.

• Progesterone, which must accompany estrogen if you still have your uterus, can actually disrupt metabolism in some women — acting almost like a steroid.

• A flat glucose line after eating isn't the goal — your brain needs to see glucose go up to register that you've been nourished and keep your metabolism running.

• Hair loss on GLP-1 medications is more likely tied to nutrient deficiencies (especially iron and protein) than the drugs themselves.

• Lipedema is a disease of the fat tissue itself — separate from obesity — and tirzepatide may help reduce the inflammatory symptoms even though it won't eliminate the fat deposits.

Notable Quote

"If your glucose is flat line, your brain's not very convinced that you ate much — and then you're not getting the metabolic benefit." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What happens when you do everything "right" — the GLP-1, the protein shake, the tracking — and the scale still won't budge? This episode reveals why doing everything “right” might actually be a big part of the problem.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor welcome Sandy, a listener from Pennsylvania who has been on the metabolic health journey for over a year. Sandy's story is one many listeners will recognize: decades of dieting starting in childhood, a body that kept adapting against her, and a medical system that kept telling her to try harder. But when Dr. Cooper reviews Sandy's actual lab work live on air, what she finds reframes everything — and offers a path forward that has nothing to do with restriction.

Key Takeaways

• Suppressed leptin hides a portion of your body fat from your brain, and possibly signals your brain that you're underweight — so your brain fights weight loss even when your body doesn't need protecting.

• Low insulin isn't always healthy; it can be a sign of the "selfish brain" redirecting precious glucose to the brain at the expense of your muscles.

• Weight cycling — losing and regaining the same weight repeatedly — creates cardiovascular and metabolic risk.

• Mechanical eating is the antidote to disordered eating: structured, non-restrictive fueling that rebuilds metabolic trust.

• GLP-1 medications can suppress appetite, so under-eating becomes a real risk — especially for people already conditioned to restrict.

• The goal isn't the number on the scale. It's metabolic stability and metabolic health, and those things are not the same.

Notable Quote

"It was such a revelation to me to hear you guys talk about it — it's a metabolic disorder. It's not a willpower issue, it's not a personal failing. It's something absolutely beyond my control. Like diabetes would be. Like migraines would be." — Sandy

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The Science Behind the New Wegovy Pill (with Novo Nordisk’s Dr. Jason Brett)

What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.

Key Takeaways

• Oral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.

• The “30-minute rule” isn’t random—it’s part of how the pill has a chance to work as intended.

• Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”

• Pricing and access shape who can actually benefit, even when the science is strong.

• Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.

Notable Quote

"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark Wright

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Mailbag: Your GLP-1 Questions on Pregnancy, Dosing, and Why Diets Cause Fat Gain

What happens when you stop GLP-1 medications before getting pregnant? Why might your thyroid numbers change on Zepbound? And why do people gain more body fat after dieting — even when they're still eating well? Dr. Cooper tackles your toughest questions.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions covering pregnancy planning on GLP-1s, unmasked thyroid problems, injection site reactions, mechanical eating after bariatric surgery, why diets cause fat regain at a cellular level, and discussing with your doctor whether you should (or shouldn't) increase your medication dose.

Key Takeaways

• GLP-1 medications aren't causing gestational diabetes — they may have been masking underlying metabolic dysfunction that becomes visible when the medication is stopped

• Thyroid problems can be "unmasked" by GLP-1 treatment because the medications signal to your brain that you're not starving, allowing the pituitary TSH to rise, sometime uncovering a pre-existing thyroid issue

• Zepbound may improve iron absorption — if iron levels go too high, testing for hemochromatosis may be warranted

• To reduce injection site reactions: warm the medication to room temperature, clean and prep skin but don't over-rub with alcohol, inject at exactly 90 degrees, don't pinch the skin, and stay relaxed

• Diets cause fat regain at the cellular level — it's chemistry, not willpower — and the fat often accumulates in the visceral area around organs

• There's no need to increase your GLP-1 dose if you're making good progress — an annual weight loss rate of 15% or higher is considered strong

Notable Quote

"You can't think that just because somebody's weight is high, it's because something they're doing is wrong. That is just not founded in science whatsoever." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Wegovy Pill: Who's It For?

The new Wegovy pill is generating massive buzz — but is it actually better than the injection? Before you ask your doctor to switch, there are some surprising requirements that could make or break whether this option works for you.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the new oral semaglutide approved for obesity treatment. They explain how the Wegovy pill differs from Rybelsus, who's a good candidate to switch (and who isn't), the strict dosing protocol most people don't know about, and what's coming next in the GLP-1 pill landscape — including a less fussy competitor from Eli Lilly.

Key Takeaways

• The Wegovy pill uses an upgraded "version two" formulation with enhanced absorption — it's not the same as Rybelsus

• Semaglutide targets deep metabolic dysfunction, not just appetite — reducing inflammation, visceral fat, and cardiovascular risk

• The pill must be taken first thing in the morning on an empty stomach with minimal water, then nothing else for 30 minutes — breaking this protocol negates effectiveness

• The pill is slightly less effective than the highest-dose Wegovy injection, so switching isn't ideal for patients still making progress at maximum dose

• Novo Nordisk's cash pay program starts at $149/month for lower doses and $299/month for the highest dose

• Eli Lilly's upcoming orforglipron pill uses small molecule technology that won't require the strict dosing ritual

Notable Quote

"When people say it works because it just makes you eat less, that's really missing the point of the sophistication of these meds." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What if the scale isn't moving, but your health is dramatically improving?

If you've ever felt discouraged because the number on the scale won't budge—even on a GLP-1 medication—this episode will change how you think about these drugs. Dr. Cooper breaks down the research showing that the biggest benefits have nothing to do with weight loss. It's all about metabolic health.

This Week on Fat Science

Dr. Emily Cooper, Mark Wright, and Andrea Taylor explore the research proving GLP-1 medications are far more than "weight loss drugs." The team explains how cardiovascular outcome trials revealed unexpected heart protection, why inflammation reduction may be the real mechanism behind these benefits, and what the latest FDA approvals for kidney disease, sleep apnea, and fatty liver mean for patients. Plus: the new oral Wegovy pill, what's coming next in metabolic medicine, and why everyone should be screened for metabolic dysfunction regardless of weight.

What You'll Learn

• Why two-thirds of cardiovascular risk reduction from GLP-1s is completely independent of weight loss

• How these medications reduce inflammation, stabilize arterial plaque, and improve vascular function

• The difference between MASLD and MASH—and why the name change matters

• What the Flow Trial revealed about kidney protection (and why it was stopped early)

• How Zepbound earned FDA approval for sleep apnea

• Why metabolic screening should happen regardless of what the scale says

Notable Quote

"You can still become incredibly healthier even if the weight is more stubborn. So I think that's the thing, is to discuss with your doctor not 'Oh, I want to lose X amount of pounds' or 'How much weight do you think I should lose?' That is not the conversation. It's more, let's take a look at the health parameters."

— Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions from California, the UK, France, Washington, Wyoming, and beyond. 

The team breaks down why Dr. Cooper does not recommend calorie tracking (and when limited tracking can make sense), how to build confidence in eating without data, and why “mechanical eating” sometimes needs medical customization—especially for people with slow gut transit or gastroparesis-like symptoms. 

They also dig into bile acid malabsorption after gallbladder removal, when metformin side effects deserve a second look, what we currently know about COVID-19’s potential impact on metabolic health, and why metformin and GLP-1 medications can be complementary—particularly in PCOS.

Key Takeaways
• Long-term calorie tracking can override physiologic cues and reinforce diet mentality.
• Short-term, targeted tracking may be useful when guided by a clinician (e.g., nutrient deficiencies ).
• Obesity and abnormal appetite are both manifestations of metabolic dysfunction—not simple cause and effect.
• Mechanical eating is a framework, not a rigid rule—timing and food choices may need medical tailoring.
• Post-gallbladder diarrhea may reflect bile acid malabsorption and can be treatable.
• Metformin and GLP-1s often complement each other because they target different metabolic states (fasting vs fed).

Dr. Cooper’s Actionable Tips
• Stop daily calorie counting—focus on consistent patterns and metabolic nourishment.
• Use mechanical eating basics: eat every few hours, include all food groups, and reduce chemical additives when possible.
• If you’re transitioning away from tracking, consider a dietitian skilled in diet-mentality recovery.
• If frequent eating worsens sleep or bloating, work with a medical dietitian to adjust intervals and food types (especially with slow GI transit).
• If chronic diarrhea appears (especially after gallbladder removal), ask your clinician about bile acid malabsorption and treatment options.
• Use labs to guide therapy: fasting insulin can signal metformin benefit; post-meal patterns can point toward GLP-1 needs.

Notable Quote
“Once you start using tracking to stay in a calorie range or a carbohydrate range, you’re putting your brain in front of your physiologic intuition—your body is sending you important cues all the time.”
—Dr. Emily Cooper

Links & Resources

The Metabolic Links to PCOS, Release Date 2/24/25

The COVID Connection to Diabetes & Metabolic Health, Release Date 12/16/24

Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: questions@fatsciencepodcast.com

*Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

his week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions that get to the heart of metabolic health. The team explains the real difference between meals and snacks, discusses whether GLP-1 medications can be appropriate for children in complex cases, explores why some people appear to be “non-responders” to Wegovy, and breaks down why alarming headlines about rapid weight regain miss the bigger metabolic picture. They also explain how to set a goal weight using body composition, labs, and overall health—rather than the scale alone.

Key Questions Answered
• What separates a meal from a snack metabolically?
• Why can grazing all day backfire—even with healthy food?
• Are GLP-1s ever appropriate for kids?
• Why do some people feel hungrier as GLP-1 doses increase?
• How are PCOS and insulin dysregulation connected?
• What is a mixed meal tolerance test, and why does it matter?
• Do GLP-1 users really regain weight faster?
• How should goal weight be determined after major weight loss?

Key Takeaways
• Meals provide structure; snacks prevent long gaps—both matter.
• GLP-1 “non-response” often signals deeper metabolic issues.
• Weight regain reflects underlying dysfunction, not personal failure.
• Maintenance dosing must be individualized.
• Body composition matters more than BMI or scale weight.

Dr. Cooper’s Actionable Tips
• Eat structured meals with carbs, protein, and fats.
• Use snacks strategically to avoid long gaps.
• Ask about deeper glucose/insulin testing when progress stalls.
• Prioritize DEXA body composition over scale-based goals.
• Avoid compounded GLP-1s—especially in children.

Notable Quote

“If you stop treating the metabolic dysfunction, the dysfunction is still there—and the body will drive weight back to where it was headed all along.”
—Dr. Emily Cooper

Links & Resources
Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: questions@fatsciencepodcast.com

Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down two GLP-1 studies that challenge a major media myth: GLP-1 medications don’t drive weight loss just because people eat less. Instead, drugs like tirzepatide and semaglutide create direct metabolic shifts—including increased fat oxidation and improved fuel partitioning—regardless of appetite.

The team also explores mechanical eating, the psychological impact of “diet food,” and Andrea’s 13-year metabolic recovery journey.

Key Questions Answered

• If both groups are dieting, why does the tirzepatide group lose more weight?
• What is metabolic adaptation, and why does dieting slow metabolism so sharply?
• How do GLP-1s directly increase fat oxidation?
• What is mechanical eating, and why do GLP-1 users need it?
• Why does ad-lib eating produce different metabolic responses than calorie restriction?
• Can mindset alone change hunger hormones? (Yes—the milkshake study.)
• Why do diet foods and diet sodas fail to improve metabolic health?
• Why is response to GLP-1s so different from person to person?

Key Takeaways

• GLP-1s are metabolic drugs—not appetite suppressants.
  Their power comes from hormonal effects on fat burning, not reduced food intake.
• Calorie restriction still slows metabolism.
  Even on GLP-1s, dieting triggers significant metabolic slowdown.
• Ad-lib eating outperforms dieting in the research.
  Semaglutide users who ate freely did not show the extra metabolic slowdown seen in dieters.
• Mechanical eating is the most durable long-term approach.
  Regular meals and snacks protect lean mass and prevent famine signaling.
• Mindset shapes hormones.
  Believing a food is “diet” vs. “indulgent” alters ghrelin and satisfaction.
• Track body composition—not just the scale.
  DEXA scans show whether you’re losing fat, muscle, or bone.

Dr. Cooper’s Actionable Tips

• Don’t diet on GLP-1s. Focus on fueling, not restriction.
• Use mechanical eating: predictable meals and snacks, no long gaps.
• Prioritize satisfaction: diet foods often backfire hormonally.
• Follow your real-world data: long-term changes matter more than short-term scale shifts.
• Ask about body composition testing if possible.

Notable Quote:

“What that study proved is that doing the calorie restriction is causing the metabolic slowing… and that’s why it’s so confusing to me that we keep advising people to restrict calories when they’re trying to improve their metabolic function.” —Dr. Emily Cooper

Links & Resources

Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: questions@fatsciencepodcast.com
Dr. Cooper Email: dr.c@fatsciencepodcast.com

Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational only, and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle a wide-ranging mailbag episode with listener questions from the U.S., UK, and Europe. Topics include unexpected weight regain on GLP-1s, post-meal sleepiness and hypoglycemia, metabolic dysfunction despite normal labs, GLP-1 dosing strategies, and why these medications are about metabolism, not appetite suppression.

Key Questions Answered

• Why can weight regain happen on GLP-1s even when habits haven’t changed?
• How do leptin, ghrelin, injury, stress, and under-fueling affect weight regulation?
• What does it mean if you get extremely sleepy after meals—is it hypoglycemia?
• Do GLP-1s increase insulin in a harmful way for non-diabetics?
• Can you have metabolic dysfunction with normal A1C, cholesterol, and blood pressure?
• Do GLP-1 medications “wear off,” and how should dosing be adjusted long term?
• Are GLP-1s just appetite suppressants—or true metabolic treatment?
• Is it possible to undo decades of calorie counting and restriction-based thinking?
• What are the risks of the return to extreme thinness in celebrity culture?

Key Takeaways

• Calories don’t explain metabolism. GLP-1 and GIP work across the brain and body—repairing signaling, not just reducing appetite.
• Leptin matters after dieting. Years of restriction and weight cycling can weaken leptin signaling, making the brain defend weight gain.
• Fueling is foundational. Medication can’t replace adequate food, sleep, and recovery.
• Post-meal fatigue is a clue. Reactive hypoglycemia is common and often misunderstood.
• Lowest effective dose wins. GLP-1 success is about pacing, not racing to the max dose.
• Chasing the “last 10 pounds” can backfire. Cosmetic restriction can create new metabolic problems.

Dr. Cooper’s Actionable Tips

• If weight gain appears after injury or stress, focus first on sleep, regular meals, and full fueling, not restriction.
• Suspected hypoglycemia? Ask about a mixed meal tolerance test to assess glucose and insulin response.
• Stay on the lowest GLP-1 dose that’s working and adjust only when progress truly stalls.
• Push back on “appetite suppressant” language—these meds amplify hormones your body already makes.

Notable Quote

“GLP-1s aren’t about eating less—they’re about strengthening metabolic signaling” — Dr. Emily Cooper

Links & Resources

Podcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/

Podcast Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Show Question: questions@fatsciencepodcast.com
Dr. Cooper direct show email: dr.c@fatsciencepodcast.com

Fat Science breaks diet myths and advances the science of real metabolic health. No diets, no agendas—just science that makes you feel better. This show is informational only and does not constitute medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with pediatric eating disorder specialist Dr. Julie O’Toole (Kartini Clinic) and pediatric obesity expert Dr. Evan Nadler about what childhood obesity really is: a biologic, metabolic disease—not a willpower problem and not a failure of parenting.

They explore how excess weight, constant hunger, and disordered eating in kids are often signs of underlying metabolic dysfunction and genetics—and why the old “eat less, move more” advice can do real harm, especially when children are shamed or restricted in the name of “health.”

Key Questions Answered

• Why is childhood obesity a metabolic disease, not a behavior problem?
• How are obesity and eating disorders deeply connected instead of opposite extremes?
• What role do GLP-1 medications play in children—and how do we protect against under-fueling?
• When should parents suspect genetic drivers like hyperphagia or MC4 mutations?
• How can medical treatment for obesity actually reduce disordered eating behaviors?
• When does excess weight become a medical issue requiring metabolic evaluation—not another diet?

Key Takeaways

• Weight is a symptom. Childhood obesity is often a sign of metabolic dysfunction, not overeating.
• Obesity & eating disorders overlap. Restriction can trigger disordered eating; disordered eating can worsen obesity.
• “Eat less, move more” harms. Shame-based approaches delay treatment and increase risk of eating disorders.
• GLP-1s work metabolically, not just through appetite suppression. Kids still need consistent fueling.
• Genetics matter. Single-gene differences can drive severe childhood hunger & rapid weight gain.
• Not treating is harm. Avoiding obesity care violates first, do no harm.

Dr. Cooper’s Actionable Tips

• If your child is gaining weight or constantly hungry, request metabolic labs (insulin, glucose, lipids, liver, hormones).
• If the doctor only says “eat less, move more,” ask: “How are we evaluating metabolism and genetics?”
• On GLP-1s? Monitor for under-fueling (skipped meals, low energy, food anxiety) and intervene promptly.

Notable Quote

“Not treating childhood obesity is doing harm. It’s a disease, not a lifestyle choice.” — Dr. Evan Nadler

Links & Resources

• Podcast Home: Fat Science Website
• Episodes & Show Archive: Cooper Center Podcast Page
• Education & Metabolic Resources: coopermetabolic.com/resources
• Submit a Show Question: questions@fatsciencepodcast.com
• Email Dr. Cooper Directly: dr.c@fatsciencepodcast.com

Connect with Our Guests

Dr. Evan P. Nadler, MD, MBA – Founder, ProCare Consultants & ProCare TeleHealth
Website: obesityexplained.com
YouTube Channel: Obesity Explained

Dr. Julie K. O’Toole, M.D., M.P.H. – Chief Medical Officer & Founder, Kartini Clinic
Website: kartiniclinic.com
Books: amazon.com/author/julieotoole

*Fat Science breaks diet myths and advances the science of real metabolic health. No diets. No agendas. Just science that makes you feel better. This episode is informational only and not medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with exercise physiologist Russell Cunningham and patient Becca Wert about a counterintuitive reality: for some people, exercise can actually slow metabolism, stall weight loss, and trigger weight gain—especially when the brain senses a threat to energy availability. 

Dr. Cooper explains how overtraining, under-fueling, and even thinking about workouts can activate famine signals in the brain and shut down key hormone pathways and what it takes to rebuild trust so movement becomes helpful instead of harmful.

Key Questions Answered

• How can exercise trigger metabolic slowdown and weight gain instead of weight loss?
• What lab markers (leptin, ghrelin, thyroid, cortisol, sex hormones) signal that your body is in “conservation mode”?
• Why did Becca lose more than 120 pounds after stopping intense workouts—and what did her COVID experience reveal about her metabolism?
• How did Russell’s overtraining syndrome develop, and what did his recovery teach him about fueling, rest, and nervous system regulation?
• How should fueling before, during, and after activity look different for people who are highly sensitive to energy deficits?
• When is it time to pull back on exercise, even if every message you’ve heard says “move more”?

Key Takeaways

• Exercise is stress, not magic. When the brain perceives low energy or famine risk, it can respond to exercise by slowing metabolism, shutting down hormones, and defending body fat.
• Labs tell the story. Low leptin with high “famine signals,” along with thyroid, cortisol, and reproductive hormone suppression, are red flags that the body is conserving energy—not freely burning fuel.
• Fueling beats punishment. For sensitive metabolisms, you often “can’t overdo the fueling” around movement—sports drinks and carbs, even for short sessions, can help reassure the brain that it’s safe.
• Movement ≠ grind. Reframing exercise as enjoyable movement and nervous system regulation (walking, gentle climbing, yard work) helps break from all-or-nothing “training” mindsets that can backfire.

Dr. Cooper’s Actionable Tips

• If your weight climbs or stalls despite hard workouts and restricted eating, talk with a clinician about metabolic labs instead of just pushing harder.
• Cushion any exercise with real fuel: eat before, add carbs/electrolytes during, and refuel after—especially if you have a history of dieting, overtraining, or weight cycling.
• Consider starting with low-intensity, pleasant movement and always “leave gas in the tank” instead of chasing exhaustion as the goal.

Notable Quote“Exercise should not be used as a weight loss tool. It should be used as a performance and a health tool.” — Dr. Emily Cooper

Links & ResourcesPodcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.com

Fat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor unpack the biggest GLP-1 headlines from around the world—from the World Health Organization’s first-ever GLP-1 obesity guidelines to access battles, brain research, and the coming wave of generics and new meds.

Dr. Cooper explains what the WHO’s move really means for patients, why long-term treatment matters, and how policy decisions in places like California and India could reshape who actually benefits from these breakthroughs. This isn’t hype—it’s metabolic medicine, health-system reality, and grounded hope.

Key Questions Answered

• Why is the WHO’s new guidance on GLP-1s for obesity such a historic turning point?
• What does it mean to treat obesity as a chronic, relapsing disease—not a willpower problem?
• Why do GLP-1s usually need to be taken long term, and how is that similar to blood pressure or cholesterol meds?
• How should GLP-1s be paired with metabolic care—fueling, sleep, movement, and real clinical oversight?
• What did the “stone cold negative” Alzheimer’s trials show—and why are addiction trials still promising?
• How could India’s launch of Ozempic and future generics impact global pricing and access?
• What new GLP-1 and metabolic drugs are on the horizon (like orforglipron, higher-dose oral semaglutide, and GLP-1/amylin combos)?

Key Takeaways

• WHO is catching up to the science. Obesity is affirmed as a chronic, relapsing disease that deserves pharmacologic treatment—not “eat less, move more” lectures or moral judgment.
• Long-term meds are the rule, not the exception. Stopping GLP-1s usually leads to weight and risk factors returning, just like stopping blood-pressure meds. That’s physiology, not failure.
• Behavior ≠ blame. WHO calls for pairing GLP-1s with “behavioral” care—but Dr. Cooper reframes this around fueling, sleep, and supported habits, not deprivation or diet culture.
• Access is the battleground. Even as WHO elevates GLP-1s, programs like California’s Medi-Cal are cutting coverage for obesity, a move Dr. Cooper calls penny-wise and pound-foolish given the downstream costs of diabetes and cardiovascular disease.
• Brain outcomes are nuanced. Large oral semaglutide trials failed to slow Alzheimer’s, but GLP-1s (and other obesity meds) still show promise for addiction by modulating reward pathways and the “internal drug factory” (POMC).
• Global markets are shifting. India’s huge population, looming Ozempic patent expirations, and emerging generics could eventually drive prices down—especially as more manufacturers compete.
• New meds may expand options. Orforglipron (a small-molecule oral GLP-1), higher-dose oral semaglutide, and a weekly GLP-1/amylin combo could bring more flexible, powerful, and potentially more affordable tools.

Dr. Cooper’s Actionable Tips

• Think of obesity treatment like any chronic disease: long-term, medical, and individualized—not a short-term “diet.”
• If you’re using a GLP-1, pair it with real metabolic care: consistent fueling (not under-eating), good sleep, and appropriately fueled exercise.
• Be cautious with “cheap” or unsanctioned online GLP-1 options—especially if you’re being squeezed out of coverage. Safety and oversight matter.
• Remember there are other evidence-based obesity meds beyond GLP-1s; if you can’t tolerate or access one class, ask your clinician about alternatives.

Notable Quote

“Your metabolism is a lifelong issue. It’s not a headache.”
— Andrea Taylor

Links & Resources

• Podcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/ 
• Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/ 
• Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/ 
• Submit a Show Question: questions@fatsciencepodcast.com
• Dr. Cooper direct show email: dr.c@fatsciencepodcast.com

*Fat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what’s really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.

Key Questions Answered

• If my BMI doesn’t “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?
• Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?
• If diets damage metabolism, what do you do when you’re already 80 pounds overweight?
• How long does it take for leptin and ghrelin to stabilize with mechanical eating?
• How can someone gain weight on 1,200 calories/day?
• After sleeve gastrectomy, how do you eat enough while on a GLP-1?
• Is set point theory real—and how does the melanocortin pathway influence it?
• If obesity runs in my family, will I need meds like Zepbound for life?
• How do trauma and stress alter long-term metabolic health?
• Can GLP-1s offset weight gain from steroids, mood meds, or hormones?
• Why might Ozempic work well while Mounjaro causes weight gain?

Key Takeaways

1. BMI rules don’t reflect metabolic truth.
A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.

2. Weight cycling is metabolically stressful.
Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.

3. Obesity is a multi-hormonal disease.
Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.

4. Metabolic adaptation is powerful.
Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.

5. After bariatric surgery or on GLP-1s, frequency matters.
Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.

6. Set point changes with better signaling.
GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.

7. Genetics often mean lifelong support.
Family patterns of obesity usually indicate long-term need for metabolic medication.

8. Trauma amplifies metabolic risk.
Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.

9. Medications can cause weight gain—GLP-1s can help counteract it.
Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.

10. “Newer” isn’t always better.
Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.

Dr. Cooper’s Actionable Tips

• Request deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.
• Stop restrictive dieting permanently—mechanical eating protects metabolic stability.
• Work with a fueling-focused dietitian (often ED-trained).
• Review your medication list for drugs known to cause weight gain.
• Don’t switch GLP-1s or chase higher doses if your current regimen works.

Notable Quote

“Obesity isn’t a willpower problem. It’s a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily Cooper

Links & Resources

• Podcast Home: Fat Science Podcast Website
• Submit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
• Dr. Emily Cooper on LinkedIn
• Mark Wright on LinkedIn
• Andrea Taylor on Instagram

Fat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with Maria from Buffalo, a longtime listener who shares her lifelong journey with obesity, psoriatic arthritis, and binge eating—and how finally understanding the science of metabolism gave her hope. Maria describes early childhood weight gain, joint damage, and years of restrictive dieting and food shame, then explains how GLP‑1 therapy (Zepbound) plus mechanical eating helped her lose about 50 pounds while eating more food, more often, and with more joy. 

Dr. Cooper breaks down the underlying biology—leptin, weight set point, the melanocortin pathway, and the impact of pain, sleep, and chronic inflammation on hunger hormones—and reframes obesity as a symptom of deeper metabolic problems, not a character flaw. This episode doubles as a practical, emotionally honest guide for patients trying to navigate a traditional health‑care system without a dedicated metabolic specialist.

Key Questions Answered

• How can rapid childhood weight gain, autoimmune disease, and early joint damage signal serious metabolic dysfunction rather than “too much food” or “not enough exercise”?

• What is leptin, what does “too low for your size” mean, and how does that affect hunger, weight set point, and weight loss?

• What is monogenic obesity testing, who might qualify for free genetic screening, and how can results inform (but not necessarily change) treatment?

• How do GLP‑1 medications like Zepbound work with mechanical eating so someone can lose weight while eating more regularly and with more variety?

• Which labs (fasting glucose, insulin, leptin, etc.) help uncover hidden metabolic issues, and when is a mixed‑meal test more useful than a simple fasting snapshot?

• When should brain‑active medications (such as bupropion/naltrexone combinations) be considered, and what trade‑offs and side effects matter?

• How can patients respectfully push for tests, challenge old “eat less, move more” advice, and set boundaries around weigh‑ins and stigmatizing language?

Key Takeaways

• It’s not your fault: Rapid childhood weight gain and early‑onset obesity often reflect serious metabolic biology, including rare gene variants, growth phases, and hormone signaling—not gluttony or laziness.

• Obesity is a symptom: Excess weight is better understood as a side effect of underlying metabolic fires (leptin issues, insulin resistance, brain signaling problems) that need proper diagnosis and treatment.

• Leptin really matters: Low leptin for your size can act as a biological brake on weight loss, and chronic dieting, under‑fueling, over‑exercise, and some high‑dose supplements can suppress it further.

• GLP‑1s plus mechanical eating: Medications like Zepbound can quiet food noise and support weight loss, but scheduled, balanced eating is essential to avoid under‑fueling, protect muscle, and support hormones.

• Pain and sleep are metabolic: Chronic pain and poor sleep increase hunger hormones like ghrelin and disrupt repair processes, worsening metabolic dysfunction unless directly addressed.

• Script your visits: Bring a printed list of diagnoses, medications, and questions; use patient portals to request specific tests; and practice simple boundary phrases around weighing and diet talk.

Notable Quote
“This isn’t all just caused by diets and things like that. There was an original metabolic problem. It was amplified because of the food restriction and the psychology around it, but you are a product of cumulative insults to your system—not a moral failure.” — Dr. Emily Cooper

Links & Resources

• Podcast Home: https://fatsciencepodcast.com/

• Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/

• Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/

• Submit a Show Question: questions@fatsciencepodcast.com

• Dr. Cooper direct show email: dr.c@fatsciencepodcast.com

Fat Science is informational only and does not constitute medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor field your most urgent metabolic health questions—exploring care advocacy, novel drug use, lab results, and how to filter fact from fiction in the TikTok age. 

Dr. Cooper offers clinical clarity, real-world perspective, and actionable hope—with an emphasis on what truly matters for your long-term health and energy.

Hear from listeners experiencing real breakthroughs (and challenges) with GLP-1s, get tips for navigating confusing cholesterol results, and learn why self-advocacy and good science matter more than credentials or hype. This is not a quick-fix episode; it’s real metabolic medicine, mythbusting, and grounded encouragement for your health journey.

Key Questions Answered

• What labs and scores best assess your true metabolic risk—and how do you make sense of fasting glucose, glucose-insulin ratio (GIR), and FIB-4?
• How can you find a medical provider who’ll actually give you the time and attention metabolic care requires?
• Why do GLP-1s benefit more than weight loss alone? Listeners report help with sleep apnea, inflammation, and food noise—what does the science say?
• How should you reintroduce carbs after restriction, and what’s the safest way to monitor (beyond A1C)?
• What’s up with rising cholesterol on Zepbound, and when do you worry?
• Does serotonin syndrome relate to GLP-1s? (Short answer: No—Dr. Cooper explains why.)
• What are the dangers of “GLP-1 microdosing” as pushed by social media, and what happens when influencers overstep good science?

Key Takeaways

• Care that cares: The best doctor isn’t always the most credentialed—find someone, MD, NP, or PA, who takes your questions seriously and goes deeper than the surface. 
• Labs that matter: Fasting glucose, insulin, GIR, HbA1c, plus advanced lipid testing (CardioIQ, NMR) are critical for uncovering hidden risk—not just chasing numbers. 
• GLP-1s act broadly: Listeners see gains in sleep, inflammation, and appetite regulation. These benefits are real, not just anecdotal, and Dr. Cooper shares the clinical rationale. 
• Smart fueling, even on GLP-1s: If you lack hunger cues, “mechanical eating” prevents under-fueling and cellular stress—especially important for maintaining muscle and metabolism. 
• Rethinking “microdosing”: TikTok trends are not medical advice—microdosing with black-market GLP-1s is unproven, poorly regulated, and potentially unsafe. Rely on trusted, legal medication sources only. 

Dr. Cooper’s Actionable Tips

• Request a full panel for metabolic health: ask your provider about fasting insulin, GIR, HbA1c, lipids, and FIB-4—even if you haven’t been flagged as “at risk”. 
• For those on GLP-1s: Don’t skip meals; create a schedule with protein and fiber to avoid muscle loss and ensure micronutrient intake. 
• Experiencing cholesterol shifts on medication? Ask for a breakdown (HDL, LDL, particle size) and consider advanced panels (CardioIQ, NMR) to better understand your risk. 
• If reintroducing carbs after restriction, pair them with protein or fat and test glucose/insulin at intervals post-meal to personalize your plan. 
• Avoid unregulated “microdosing” and buy only from reputable, FDA-approved outlets—protect your long-term health over quick fixes. 

Notable Quote

“The most important thing is somebody who cares, not necessarily their degrees.”— Dr. Emily Cooper

Links & Resources

Podcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Dr. Emily Cooper on LinkedIn
Mark Wright on LinkedIn
Andrea Taylor on Instagram
Advanced cholesterol testing: CardioIQ at Quest, NMR at LabCorpFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice. 

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dive into your burning questions from around the world—exploring misunderstood metabolic problems, hard-won solutions for real people, and the science behind the headlines. From “selfish brain” physiology to the rollercoaster of insurance and medication access, Dr. Cooper brings clinical clarity and practical hope.

Hear real-world listener stories, get advice on tuning your metabolic health, and learn why personalization—not “calories in, calories out”—leads to better outcomes. This is no silver bullet show: it’s metabolic medicine, mythbusting, and science-backed encouragement for your journey.

Key Questions Answered

• What is the “selfish brain” and how does it really impact blood sugar and diabetes risk?
• Why do GLP-1 medications affect stamina and hunger, and how should you fuel your body if you’re using them?
• If insurance pulls coverage for medications like Ozempic or Zepbound, what are your practical, safe, and affordable options?
• How do metabolic markers, medication “cocktails,” and genetic testing shape Dr. Cooper’s individualized care—and can you taper off meds and maintain results?
• What does “normal” blood sugar look like after meals, and how do you distinguish trends from outliers?

Key Takeaways

• Metabolism is complex—individualized care is essential. Diabetes, hypoglycemia, and insulin resistance all have personal causes and require testing like the Mixed Meal Tolerance Test to solve—not one-size-fits-all advice. 
• GLP-1s require smart fueling. Many experience reduced stamina on these medications. Dr. Cooper recommends upping both complex and simple carbs pre-exercise and consulting with a registered dietitian if fatigue persists. 
• Insurance coverage is a challenge—but not the end. Generic options (like liraglutide/Victoza via Mark Cuban Cost Plus Drugs), manufacturer programs, and “cocktail” regimens can support continued progress, even if you lose access to top-brand GLP-1s. 
• Feedback loops & genetics drive lasting outcomes. While some patients can successfully—slowly—taper medications, most with metabolic dysfunction will need long-term support. “Clean eating” alone rarely reverses underlying feedback loop glitches. 
• Monitoring is powerful. Using blood sugar monitors (especially for diabetics) can demystify meal spikes and help fine-tune nutrition and medication timing. 
• Personal stories reflect broader truths. Listeners share struggles and solutions, reinforcing that metabolic health spans medication, motivation, and mindset.

Dr. Cooper’s Actionable Tips

• Always dig deeper with testing—not just A1C but also post-meal spikes via the Mixed Meal Tolerance Test.
• If you’re prescribed a GLP-1 and struggle with energy, increase carb intake safely and talk to a doctor about medication adjustment. 
• For lost coverage, stick to FDA-approved sources: Lilly Direct for Zepbound, Novocare for Wegovy, and Mark Cuban for generics. Don’t risk unregulated online compounds. 
• Recognize the difference between generalized “healthy” habits and targeted strategies that actually move your biomarkers.
• Stay consistent and compassionate—focus on small improvements over extremes and absolutes.

Notable Quote

“The metabolism is regulated by a feedback loop…when you introduce outside hormone forms, you strengthen signals to favor fuel utilization over energy conservation.”— Dr. Emily Cooper

Links & Resources

• Podcast Home: Fat Science Podcast Website
• Submit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
• Dr. Emily Cooper on LinkedIn
• Mark Wright on LinkedIn
• Andrea Taylor on Instagram
• Generic medication access: Mark Cuban Cost Plus Drugs
• Zepbound direct: Lilly Direct
• Additional info: Novocare for Wegovy

Fat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor take a trip to the past when Dr. Cooper didn’t have many supporters in medicine. She shares what it was like to be ridiculed by her peers, why she refused to give up on her patients, and how her science-based approach to metabolism was finally validated by mainstream medicine.

Hear the raw, unfiltered story of resilience, patient advocacy, and scientific discovery that led Dr. Cooper from being dismissed as “voodoo” to blazing a trail for real metabolic health.

Key Questions Answered:

• Why did so many in the medical community reject Dr. Cooper’s methods—like challenging “calories in, calories out”—when she started treating metabolic issues?
• What does the rise of GLP-1 medications reveal about the true science behind appetite, metabolism, and weight?
• How did Dr. Cooper hold onto her integrity and keep practicing effective, patient-centered medicine despite overwhelming opposition?
• When does medical “common sense” get replaced by real science, and what does that mean for anyone struggling with diets that fail?

Key Takeaways:

• Progress means facing skepticism. Dr. Cooper was once called a "voodoo doctor" and even yelled at by other physicians for her scientific methods, but results spoke louder than her critics. 
• Metabolism is personal and complex—restrictive diets and “eat less, move more” advice often backfire. Hormonal science and careful patient tracking revealed why old rules failed. 
• Persistent curiosity and data-driven practice, not popularity, eventually shift the culture. Dr. Cooper leaned on a “matrix” of metabolic markers long before these tests were commonplace. 
• GLP-1 medications (like Byetta and Victoza) have moved from obscure tools to mainstream, validating Dr. Cooper’s approach to treating the whole metabolic system. 
• True healing means fueling, not restricting. “Eating more,” not less, was key to metabolic recovery for many patients—a radical, often ridiculed idea that’s now supported by science and real-world clinical data from thousands of patients.
• Patient stories mirror the medical journey—today, both patients and providers can look back and realize that “voodoo” was simply science ahead of its time. 

Dr. Cooper’s Actionable Tips:

• Question easy answers—when in doubt, follow the data, not tradition.
• Find a provider who listens, tests, and adapts treatment to you—not just your weight or a number on a scale.
• Remember that real science can be lonely before it’s mainstream. Trust progress, even when it feels slow.
• Celebrate freedom from food guilt; focus on nourishment, steady energy, and self-compassion, not dieting extremes.

Notable Quote:

“It does make you feel lonely because you feel like there’s no one to talk to, but it was always about doing right by the science and by my patients.” — Dr. Emily Cooper

Fat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only, not medical advice.

Check out our website to submit a question, explore resources, or reach our hosts.

Have questions for Dr. Cooper, a show idea, or feedback?Email questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com.

Connect with:
Dr. Emily Cooper on LinkedIn
Mark Wright on LinkedIn
Andrea Taylor on Instagram

his week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the biggest listener questions about sustainable weight loss, metabolic health, and why restrictive diets so often backfire. From medications like GLP-1s to common myths about exercise and nutrition, this episode delivers practical science and down-to-earth advice for anyone struggling with their weight and/or health.

Dr. Cooper breaks down why obesity is a physical sign of underlying metabolic dysfunction and sets the record straight about what really works for long-term health—spoiler: it’s not endless calorie counting or exercise alone. Listeners from around the world share their struggles and triumphs, and Dr. Cooper explains the roles of genetics, “food noise,” dealing with hypoglycemia, and the best ways to fuel your body.

Key Questions Answered:

• Can someone with obesity achieve lasting weight loss without medication? Why don’t diets and exercise alone work long-term?
• What is reactive hypoglycemia after gastric bypass, and how should it be managed?
• How can people with limited access to healthcare still improve metabolic health?
• What is “food noise,” and how do new medications target the brain’s hunger and satiety signals?
• Should people use calorie restriction or focus on fueling their bodies for better metabolic health?

Key Takeaways:

• Obesity is best understood as a physical sign of metabolic disease, not a personal failure.
• There is no diet or exercise program shown to sustain long-term weight loss for those with obesity—medical therapies are usually necessary. 
• Caloric restriction and exercise without medical intervention can slow metabolism and drive weight regain (the “diet backlash” effect). 
• Good metabolic health is possible at any body size. Nutrition, physical activity, sleep, and stress management are essential but cannot, by themselves, reverse obesity.
• Medications like GLP-1s can help “quiet” food noise by restoring healthy communication between the gut and brain.
• Lifestyle strategies support metabolic function but aren’t strong enough to reverse metabolic disease alone. Focus on eating regular meals, balanced nutrients, and fueling your activity—not on perfection or restriction.

Dr. Cooper’s Actionable Tips:

• Find a clinician who listens and is curious about your health, not just weight or calorie intake.
• Don’t be pressured to take medication if you feel healthy and have good lab results, regardless of your weight.
• Fuel your body consistently with a mix of protein, healthy fats, and complex carbs—perfection isn’t necessary.
• Prioritize sleep and stress management, as both are critical for metabolism.

Notable Quote:"There is no diet or exercise program that leads to long-term weight loss in someone with obesity. There isn't. Any time you're introducing that restriction you're opening the door to what's called metabolic adaptation, a slowing of the metabolic system. Why would you want to do that? If your whole goal is to strengthen the metabolic system, why would we want to introduce something that's been proven scientifically to slow the metabolic system down?" — Dr. Emily Cooper

Resources from the episode:Fat Science is your source for understanding why metabolic health—not weight alone—matters more than ever. No diets, no agendas, just science that makes you feel better. This show is informational only, not medical advice.

Check out our website to submit a question to the listener mailbag.

Have questions for Dr. Cooper, a show idea, feedback, or just want to connect?Email questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com.

Connect with:
Dr. Emily Cooper on LinkedIn
Mark Wright on LinkedIn
Andrea Taylor on Instagram